GIA
AEON icon

GHP Investment Advisors’s AEON Biopharma AEON Stock Holding History

GHP Investment Advisors’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69 Hold
95
– – ﹤0.01% 1321
2026
Q1 		$94 Hold
95
– – ﹤0.01% 1309
2025
Q4 		$105 Hold
95
– – ﹤0.01% 967
2025
Q3 		$77 Buy
95
+71
+296% +$55 ﹤0.01% 935
2025
Q2 		$19 Buy
24
+9
+60% +$5 ﹤0.01% 940
2025
Q1 		$9 Hold
15
– – ﹤0.01% 951
2024
Q4 		$592 Hold
15
– – ﹤0.01% 941
2024
Q3 		$1.15K Hold
15
– – ﹤0.01% 907
2024
Q2 		$1.15K Hold
15
– – ﹤0.01% 890
2024
Q1 		$12.7K Hold
15
– – ﹤0.01% 635
2023
Q4 		$7.88K Hold
15
– – ﹤0.01% 673
2023
Q3 		$6.74K Buy
+15
New +$6.87K ﹤0.01% 745

Other funds holding AEON

FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

GHP Investment Advisors's AEON Position: Q2 2026 in Review

GHP Investment Advisors held its AEON Biopharma (AEON) position steady in Q2 2026 at 95 shares worth $69. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

GHP Investment Advisors first reported a position in AEON in Q3 2023 and has held it in 12 quarters since. The position peaked at $12.7K in Q1 2024. 5 funds tracked by Wall St. Rank hold AEON as of Q2 2026.

  • GHP Investment Advisors held 95 shares of AEON Biopharma worth $69 as of Q2 2026.
  • GHP Investment Advisors left its AEON Biopharma share count unchanged in Q2 2026.
  • AEON Biopharma made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #1321 holding.
  • GHP Investment Advisors first reported a position in AEON Biopharma in Q3 2023 and has held it in 12 quarters since.
  • GHP Investment Advisors's AEON Biopharma position peaked at $12.7K in Q1 2024.
  • 5 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.